HEALTHY U CHIP

PRIOR AUTHORIZATION REQUEST FORM

ANKYLOSING SPONDYLITIS

Avsola®, Cimzia®, Cosentyx®, Enbrel®, Hadlima™, Humira®, Inflectra®, infliximab, Remicade®, Renflexis®, Rinvoq®, Simlandi®, Simponi®, Taltz®, Xeljanz/XR®

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U CHIP Prior Authorization Department.

- For **Medical Pharmacy** please fax requests to: 801-213-1547
- For **Retail Pharmacy** please fax requests to: 385-425-4052

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for Pharmacy Customer Service for assistance at 385-425-5094

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		HCPCS Code:

Member must try formulary preferred drugs before a request for a non-formulary drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Preferred/Non-Formulary:

1. **1st Line Preferred agents:**
   A. Hadlima™ (adalimumab-bwwd), Simlandi® (adalimumab-ryvk)
   B. Infliximab products: Avsola® (infliximab-axxq), Inflectra® (infliximab-dyyb), infliximab, Remicade (infliximab), Renflexis® (infliximab-abda)
2. **2nd line preferred agents with single step; after trial and failure of BOTH Hadlima™ or Simlandi®, and a preferred infliximab agent:**
   A. Cimzia® (certolizumab), Humira® (adalimumab), Taltz® (ixekizumab), Xeljanz/XR® (tofacitinib)
3. **Non-Formulary agents with a triple step; after trial and failure of Hadlima™ or Simlandi®, and a preferred infliximab agent, and 2 second line agents:**
   A. Cosentyx® (secukinumab), Enbrel® (etanercept), Rinvoq® (upadacitinib), Simponi® (golimumab)

Product being requested: _____

Dosing/Frequency:_____

If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
1. Is the member 18 years of age or older with Ankylosing Spondylitis?	☐	☐	**Please provide documentation**
2. Is the requesting provider a rheumatologist or in consultation with one?	☐	☐	
3. Does documentation show an adequate trial and failure of at least one prescription strength nonsteroidal anti-inflammatory	☐	☐	**Please provide documentation**

drug (NSAID) at the maximally tolerated dose, unless contraindicated?			
4. Has the provider performed tuberculosis (TB) screening prior to therapy initiation?	☐	☐	**Please provide documentation**
5. If the request is for a tumor necrosis factor inhibitor, has the provider performed hepatitis B screening prior to therapy initiation?	☐	☐	**Please provide documentation**
6. If the request is for Rinvoq or Xeljanz/XR, does documentation show inadequate response or intolerance to at least one TNF (tumor necrosis factor) blocker such as an infliximab product, Cimzia, an adalimumab product and/or Simponi?	☐	☐	**Please provide documentation**
REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	☐	☐	
2. Does updated documentation show that the member has a continued medical need?	☐	☐	**Please provide documentation**
3. Does updated documentation show the member responded to therapy, such as a decrease in disease severity or disease stabilization in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) or the Ankylosing Spondylitis Disease Activity Score (ASDAS)?	☐	☐	**Please provide documentation**
4. Has the provider performed continued tuberculosis screening during therapy?	☐	☐	**Please provide documentation**
5. Has the provider performed continued Hepatitis B monitoring in HBV carriers?	☐	☐	**Please provide documentation**
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician's Signature:			

****Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy: PHARM-CHIP-003
Origination Date: 07/01/2024
Reviewed/Revised Date: 09/18/2024
Next Review Date: 09/18/2025
Current Effective Date: 10/01/2024